Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
January 28, 2022
RegMed Investors’ (RMi) closing bell: a daily reversal with a big positive sector close after a frustrating week for cell and gene therapy investors
January 26, 2022
RegMed Investors’ (RMi) closing bell: I loved the smell of appreciation in the morning until the algorithms napalmed the cell and gene therapy sector
January 25, 2022
RegMed Investors’ (RMi) closing bell: wild volatility charges the slips and slides as the sector’s come-back collapses
January 24, 2022
RegMed Investors’ (RMi) closing bell: panic sector selling and then a major comeback
January 21, 2022
RegMed Investors’ (RMi) closing bell: sector trades accelerate risk aversion tumbles
January 20, 2022
RegMed Investors’ (RMi) closing bell: finally, the oversold were appreciative until the lower reverse unfolded
January 19, 2022
RegMed Investors’ (RMi) closing bell: a tightening cycle
January 18, 2022
RegMed Investors’ (RMi) closing bell: wipe-out
January 14, 2022
RegMed Investors’ (RMi) closing bell: a late session rebound, a bouncing sector rotates to close positive
January 13, 2022
RegMed Investors’ (RMi) closing bell: sector is still shackled by selling
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.